Alnylam Loses Patent Dispute in Europe
Luke Timmerman1/20/09
Cambridge, MA-based Alnylam Pharmaceuticals, a leading developer of drugs using RNA interference technology, said today it lost an oral argument that it should be granted a particular patent in Europe from its Kreutzer-Limmer patent estate. The final decision on the patent, known as ’945, is still subject to further appeal, Alnylam said in a statement. Still, the company’s shares (NASDAQ: ALNY) fell 10 percent to $20.70 at 2:50 pm Eastern time.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
